← Leaderboards
Kah-Whye Peng
Mayo Clinic Rochester
$11,311,466
Attributed
$18,857,434
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,857,434 · 12
By mechanism
R01$10,861,704 · 6
UH3$3,058,722 · 1
P50$2,806,321 · 2
UG3$1,395,173 · 1
R44$731,514 · 1
R13$4,000 · 1
Top collaborators
- Evanthia Galanis9 shared
- Jamie N Bakkum-Gamez5 shared
- Matthew Stephen Block5 shared
- Keith L Knutson5 shared
- Nabila Nora Bennani3 shared
- William S Brimijoin3 shared
- W. Michael Hooten1 shared
- Stephen J Russell1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Jamie N Bakkum-Gamez$820,154
- Nabila Nora Bennani$914,136
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusDoseCellsSafetyAntibodiesTumorOncolyticMonitorInfectionImageMultiple MyelomaEngineeringNeoplastic CellXenograft ProcedureMalignant Neoplasm Of OvaryGrantMalignant NeoplasmsViralMeaslesCancer TherapyGenesMediatingIntravenousViral Genes
Grant awards (44)
Intravenous VSV virotherapy in lymphoma$619,753
R01 · FY2025 · CA · contact PI
Intravenous VSV virotherapy in lymphoma$588,765
R01 · FY2024 · CA · contact PI
Intravenous VSV virotherapy in lymphoma$619,753
R01 · FY2023 · CA · contact PI
Definitive Preclinical Studies of Hydrolase Gene Transfer to Treat Cocaine Abuse$853,821
UH3 · FY2021 · DA · contact PI
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$373,073
R01 · FY2021 · CA
Definitive Preclinical Studies of Hydrolase Gene Transfer to Treat Cocaine Abuse$853,821
UH3 · FY2020 · DA · contact PI
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$543,708
R01 · FY2020 · CA
Definitive Preclinical Studies of Hydrolase Gene Transfer to Treat Cocaine Abuse$1,351,080
UH3 · FY2019 · DA · contact PI
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$527,396
R01 · FY2019 · CA
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$543,708
R01 · FY2018 · CA
Definitive Preclinical Studies of Hydrolase Gene Transfer to Treat Cocaine Abuse$1,395,173
UG3 · FY2017 · DA
Phase 2: NIS proteins with altered anion specificity$731,514
R44 · FY2017 · TR · contact PI
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer$472,577
R01 · FY2017 · CA
Intravenous Administration of Vesicular Stomatitis Vectors$352,711
R01 · FY2017 · CA · contact PI
Intravenous Administration of Vesicular Stomatitis Vectors$336,142
R01 · FY2016 · CA · contact PI
Intravenous Administration of Vesicular Stomatitis Vectors$352,711
R01 · FY2015 · CA · contact PI
Intravenous Administration of Vesicular Stomatitis Vectors$104,276
R01 · FY2015 · CA · contact PI
Intravenous Administration of Vesicular Stomatitis Vectors$352,711
R01 · FY2014 · CA · contact PI
Enhancing localization of therapeutic viruses and cells to tumor sites$260,508
R01 · FY2014 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$393,649
P50 · FY2013 · CA
Enhancing localization of therapeutic viruses and cells to tumor sites$344,282
R01 · FY2013 · CA · contact PI
Animal Models$171,968
P50 · FY2013 · CA
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$507,051
R01 · FY2012 · CA
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$372,958
P50 · FY2012 · CA
Enhancing localization of therapeutic viruses and cells to tumor sites$366,259
R01 · FY2012 · CA · contact PI
Animal Models$171,472
P50 · FY2012 · CA
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$424,154
R01 · FY2011 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$344,948
P50 · FY2011 · CA
Animal Models$178,889
P50 · FY2011 · CA
Enhancing localization of therapeutic viruses and cells to tumor sites$81,257
R01 · FY2011 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$530,593
R01 · FY2010 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$396,237
P50 · FY2010 · CA
Enhancing localization of therapeutic viruses and cells to tumor sites$377,586
R01 · FY2010 · CA · contact PI
Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies$255,082
R01 · FY2010 · CA · contact PI
Animal Models$188,653
P50 · FY2010 · CA
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$529,522
R01 · FY2009 · CA
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$398,680
P50 · FY2009 · CA
Enhancing localization of therapeutic viruses and cells to tumor sites$370,180
R01 · FY2009 · CA · contact PI
Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies$255,082
R01 · FY2009 · CA · contact PI
Animal Models$188,867
P50 · FY2009 · CA
Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies$255,082
R01 · FY2008 · CA · contact PI
Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies$255,082
R01 · FY2007 · CA · contact PI
4th International Conference on Oncolytic Viruses as Cancer Therapeutics$4,000
R13 · FY2007 · CA · contact PI
Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies$262,700
R01 · FY2006 · CA · contact PI